Jane Street Group LLC decreased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 86.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,397 shares of the specialty pharmaceutical company's stock after selling 450,311 shares during the period. Jane Street Group LLC owned approximately 0.14% of KalVista Pharmaceuticals worth $588,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock worth $262,000 after acquiring an additional 1,670 shares during the period. SG Americas Securities LLC grew its holdings in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after acquiring an additional 1,319 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after acquiring an additional 2,043 shares during the period. AlphaQuest LLC grew its holdings in shares of KalVista Pharmaceuticals by 17.1% in the 4th quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after acquiring an additional 2,588 shares during the period. Finally, Intech Investment Management LLC grew its holdings in shares of KalVista Pharmaceuticals by 58.5% in the 4th quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company's stock worth $146,000 after acquiring an additional 6,349 shares during the period.
Insider Activity
In other news, CEO Benjamin L. Palleiko sold 6,669 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the sale, the chief executive officer now directly owns 287,811 shares of the company's stock, valued at approximately $3,445,097.67. This represents a 2.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the transaction, the insider now directly owns 106,611 shares in the company, valued at approximately $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,399 shares of company stock valued at $182,054 in the last quarter. Company insiders own 10.50% of the company's stock.
KalVista Pharmaceuticals Stock Down 1.1%
Shares of KalVista Pharmaceuticals stock traded down $0.13 on Friday, hitting $11.76. 703,041 shares of the company traded hands, compared to its average volume of 427,068. The company has a 50-day moving average price of $11.90 and a 200 day moving average price of $10.47. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50. The company has a market cap of $584.66 million, a PE ratio of -3.23 and a beta of 0.05.
Wall Street Analysts Forecast Growth
KALV has been the topic of a number of analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Jones Trading reaffirmed a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $24.83.
Check Out Our Latest Report on KALV
KalVista Pharmaceuticals Company Profile
(
Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
See Also
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
